Potential Diagnostic and Prognostic Value of Lymphocytic Mitochondrial DNA Deletion in Relation to Folic Acid Status in HCV-Related Hepatocellular Carcinoma

Citation:
Zekri, A. R. N., H. Salama, E. medhat, S. Hamdy, Z. K. Hassan, Y. M. Bakr, A. S. E. D. - Youssef, D. Saleh, R. Saeed, and D. Omran, "Potential Diagnostic and Prognostic Value of Lymphocytic Mitochondrial DNA Deletion in Relation to Folic Acid Status in HCV-Related Hepatocellular Carcinoma", Asian Pacific journal of cancer prevention : APJCP, vol. 18, issue 9, pp. 2451-2457, 2017 09 27. copy at www.tinyurl.com/yzaxfz4h

Abstract:

Objective: We assessed the possibility of using mitochondrial (mt) DNA deletion as a molecular biomarker for
disease progression in HCV-related hepatocellular carcinoma (HCC) and to identify its association with folic acid status.
Methods: Serum folic acid and lymphocytic mtDNA deletions were assessed in 90 patients; 50 with HCC, 20 with
liver cirrhosis (LC), and 20 with chronic hepatitis C (CHC) compared to 10 healthy control subjects. The diagnostic
accuracy of mtDNA deletions frequency was evaluated using receiver-operating characteristic (ROC) curve analysis
Survival analysis was performed using the Kaplan-Meier method. Differences in the survival rates were compared
using log-rank test. Result: Our data revealed a significant elevation of mtDNA deletions frequency in the HCC
group compared to the other groups (P-value <0.01). Also, our data showed a significant correlation between folate
deficiency and high frequency of mtDNA deletions in patients with HCV-related HCC when compared to the other
groups (r= -0.094 and P-value <0.05). Moreover, the size of the hepatic focal lesion in the HCC patients was positively
correlated with mtDNA deletions (r= 0.09 and P-value <0.01). The median survival time for the HCC patients with
high frequency of mtDNA deletions (ΔCt ≥3.9; 5.7+ 0.6 months) was significantly shorter than those with low mtDNA
deletions frequency (ΔCt < 3.9; 11.9+ 0.04 months, P-value <0.01). Conclusion: Our data provided an evidence that
lymphocytic mtDNA deletion could be used as non-invasive biomarker for disease progression and patients’ survival in
HCV-related HCC. Also, our findings implied a causal relationship between the folate deficiency and the high mtDNA
deletions frequency among Egyptian patients with HCV related HCC.

Notes:

n/a

Tourism